---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-014919"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:09:56.657062+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics terminates at-the-market equity facility with Guggenheim; no shares ever sold

## Summary
- Terminated Sales Agreement with Guggenheim Securities effective Feb 13, 2024.
- Agreement permitted up to $50M in at-the-market common stock offerings.
- No shares of common stock were ever sold under the agreement.
- Original agreement date was November 10, 2022.

## SEC filing metadata
- accession: 0000950170-24-014919
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/0000950170-24-014919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/lrmr-20240213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-014919
- JSON: https://secwatch.observer/filing/0000950170-24-014919.json
- Plain text: https://secwatch.observer/filing/0000950170-24-014919.txt

## Key facts
- Material Agreements
  Larimar Therapeutics, Inc. terminated Sales Agreement with Guggenheim Securities, LLC valued at Aggregate offering price of up to $50,000,000; no shares sold under the agreement (effective 2024-02-13).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Guggenheim Securities, LLC
  - Value: Aggregate offering price of up to $50,000,000; no shares sold under the agreement
  - Effective: 2024-02-13
  source text: On February 13, 2024, Larimar Therapeutics, Inc. (the “ Company ”) gave notice to terminate the Sales Agreement that the Company entered into with Guggenheim Securities, LLC on November 10, 2022 (the “ Sales Agreement ”). Termination of the Sales Agreement was effective February 13, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/0000950170-24-014919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.